Pomalyst (pomalidomide) — CareFirst (Caremark)
Primary central nervous system lymphoma
Initial criteria
- Authorization may be granted for treatment of primary central nervous system lymphoma as a single agent.
Reauthorization criteria
- Authorization may be granted for continued treatment when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.
Approval duration
12 months